PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

Cancer Research

Volumn 64, Issue 3, 2004, Pages 1140-1145

  Blank, Christian ^a   Brown, Ian ^a   Peterson, Amy C ^a   Spiotto, Mike ^a   Iwai, Yoshiko ^b   Honjo, Tasuku ^b   Gajewski, Thomas F ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2C PROTEIN; ANTIBODY; ANTIGEN; B7 ANTIGEN; B7H 1 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GREEN FLUORESCENT PROTEIN; LIGAND; PD L1 ANTIBODY; PD L1 ANTIGEN; PEPTIDE; PROTEIN; RAG2 PROTEIN; SERYLISOLEUCYLTYROSYLARGINYLTYROSYLTYROSYLGLYCYLLEUCINE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; GENE EXPRESSION; GENE INDUCTION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VIVO STUDY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; T LYMPHOCYTE SUBPOPULATION; TRANSGENIC MOUSE; TUMOR CELL; TUMOR GROWTH; TUMOR REJECTION; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; BLOOD PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; INTERFERON TYPE II; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PEPTIDES; RECEPTORS, ANTIGEN, T-CELL; TRANSDUCTION, GENETIC; UP-REGULATION;

EID: 0842325739     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3259     Document Type: Article

References (40)

1. Nielsen, M. B., Monsurro, V., Migueles, S. A., Wang, E., Perez-Diez, A., Lee, K. H., Kammula, U., Rosenberg, S. A., and Marincola, F. M. Status of activation of circulating vaccine-elicited CD8+ T cells. J. Immunol., 165: 2287-2296, 2000.
2. Lee, P., Wang, F., Kuniyoshi, J., Rubio, V., Stuges, T., Groshen, S., Gee, C., Lau, R., Jeffery, G., Margolin, K., Marty, V., and Weber, J. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol., 19: 3836-3847, 2001.
3. Weber, J., Sondak, V. K., Scotland, R., Phillip, R., Wang, F., Rubio, V., Stuge, T. B., Groshen, S. G., Gee, C., Jeffery, G. G., Sian, S., and Lee, P. P. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer (Phila.), 97: 186-200, 2003.
4. Peterson, A. C., Harlin, H., and Gajewski, T. F. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J. Clin. Oncol., 21: 2342-2348, 2003.
5. Kiessling, R., Wasserman, K., Horiguchi, S., Kono, K., Sjoberg, J., Pisa, P., and Petersson, M. Tumor-induced immune dysfunction. Cancer Immunol. Immunother., 48: 353-362, 1999.
6. Ravetch, J. V., and Lanier, L. L. Immune inhibitory receptors. Science (Wash. DC), 290: 84-89, 2000.
7. Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., and Schreiber, R. D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol., 3: 991-998, 2002.
8. Gajewski, T. F., Fallarino, F., Fields, P. E., Rivas, F., and Alegre, M. L. Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase. J. Immunol., 166: 3900-3907, 2001.
9. Coles, M. C., McMahon, C. W., Takizawa, H., and Raulet, D. H. Memory CD8 T lymphocytes express inhibitory MHC-specific Ly49 receptors. Eur. J. Immunol., 30: 236-244, 2000.
10. Ugolini, S., and Vivier, E. Regulation of T cell function by NK cell receptors for classical MHC class I molecules. Curr. Opin. Immunol., 12: 295-300, 2000.
11. Nishimura, H., and Honjo, T. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol., 22: 265-268, 2001.
12. Leach, D. R., Krummel, M. F., and Allison, J. P. Enhancement of antitumor immunity by CTLA-4 blockade. Science (Wash. DC), 271: 1734-1736, 1996.
13. Kwon, E. D., Hurwitz, A. A., Foster, B. A., Madias, C., Feldhaus, A. L., Greenberg, N. M., Burg, M. B., and Allison, J. P. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA, 94: 8099-8103, 1997.
14. Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J.; Morton, K. E., Mavroukakis, S. A., Duray, P. H., Steinberg, S. M., Allison, J. P., Davis, T. A., and Rosenberg, S. A. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA, 100: 8372-8377, 2003.
15. Freeman, G. J., Long, A. J., lwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byme, M. C., Horton, H. F., Fouser, L., Carter, L., Ling, V., Bowman, M. R., Carreno, B. M., Collins, M., Wood, C. R., and Honjo, T. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med., 192: 1027-1034, 2000.
16. Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., and Honjo, T. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc. Natl. Acad. Sci. USA, 98: 13866-13871, 2001.
17. Nishimura, H., Nose, M., Hiai, H., Minato, N., and Honjo, T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity, 11: 141-151, 1999.
18. Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., and Honjo, T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (Wash. DC), 291: 319-322, 2001.
19. Yamazaki, T., Akiba, H., Iwai, H., Matsuda. H., Aoki, M., Tanno, Y., Shin, T., Tsuchiya, H., Pardoll, D. M., Okumura, K., Azuma, M., and Yagita, H. Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol., 169: 5538-5545, 2002.
20. Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., Greenfield, E. A., Bourque, K., Boussiotis, V. A., Carter, L. L., Carreno, B. M., Malenkovich, N., Nishimura, H., Okazaki, T., Honjo, T., Sharpe, A. H., and Freeman, G. J. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol., 2: 261-268, 2001.
21. Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., Lennon, V. A., Celis, E., and Chen, L. Tumor-associated B7-HI promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med., 8: 793-800, 2002.
22. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., and Minato, N. Involvement of PD-LI on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA, 99: 12293-12297, 2002.
23. Sha, W. C., Nelson, C. A., Newberry, R. D., Kranz, D. M., Russell, J. H., and Loh, D. Y. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature (Lond.), 335: 271-274, 1988.
24. Kranz, D. M., Tonegawa, S., and Eisen, H. N. Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA, 81: 7922-7926, 1984.
25. Fallarino, F., Uyttenhove, C., Boon, T., and Gajewski, T. F. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. Int. J. Cancer, 80: 324-333, 1999.
26. Gajewski, T. F. B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro. J. Immunol., 156: 465-472, 1996.
27. Ossevoort, M. A., Feltkamp, M. C., van Veen, K. J., Melief, C. J., and Kast, W. M. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J. Immunother. Emphasis Tumor Immunol., 18: 86-94, 1995.
28. Spiotto, M. T., Yu, P., Rowley, D. A., Nishimura, M. I., Meredith, S. C., Gajewski, T. F., Fu, Y. X., and Schreiber, H. Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity, 17: 737-747, 2002.
29. Udaka, K., Wiesmuller, K. H., Kienle, S., Jung, G., and Walden, P. Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J. Immunol., 157: 670-678, 1996.
30. Seliger, B., Wollscheid, U., Momburg, F., Blankenstein, T., and Huber, C. Characterization of the major histocompatibility complex class I deficiencies in B 16 melanoma cells. Cancer Res., 61: 1095-1099. 2001.
31. Dong, H., Zhu, G., Tamada, K., and Chen, L. B7-HI, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med., 5: 1365-1369, 1999.
32. Liu, X., Gao, J. X., Wen, J., Yin, L., Li, O., Zuo, T., Gajewski, T. F., Fu, Y. X., Zheng, P., and Liu, Y. B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism. J. Exp. Med., 197: 1721-1730, 2003.
33. Wang, S., Bajorath, J., Flies, D. B., Dong, H., Honjo, T., and Chen, L. Molecular modeling and functional mapping of B7-HI and B7-DC uncouple costimulatory function from PD-1 interaction. J. Exp. Med., 197: 1083-1091, 2003.
34. Loke, P., and Allison, J. P. PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. Proc. Natl. Acad. Sci. USA, 100: 5336-5341, 2003.
35. Iwai, Y., Terawaki, S., Ikegawa, M., Okazaki, T., and Honjo, T. PD-1 inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med., 198: 39-50, 2003.
36. Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., Robinson, M. R., Raffeld, M., Duray, P., Seipp, C. A., Rogers-Freezer, L., Morton, K. E., Mavroukakis, S. A., White, D. E., and Rosenberg, S. A. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (Wash. DC), 298: 850-854, 2002.
37. Chambers, C. A., Sullivan, T. J., and Allison, J. P. Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. Immunity, 7: 885-895, 1997.
38. Hayashi, R. J., Loh, D. Y., Kanagawa, O., and Wang, F. Differences between responses of naive and activated T cells to anergy induction. J. Immunol., 160: 33-38, 1998.
39. Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., Murphy, T. L., Russell, J. H., Allison, J. P., and Murphy, K. M. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol., 4: 670-679, 2003.
40. Zang, X., Loke, P., Kim, J., Murphy, K., Waitz, R., and Allison, J. P. B7x: a widely expressed B7 family member that inhibits T cell activation. Proc. Natl. Acad. Sci. USA, 100: 10388-10392, 2003.